Century Therapeutics (IPSC)
(Delayed Data from NSDQ)
$1.96 USD
-0.13 (-6.22%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.95 -0.01 (-0.51%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IPSC 1.96 -0.13(-6.22%)
Will IPSC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IPSC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPSC
Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
IPSC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?
How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4%
Organogenesis (ORGO) Reports Break-Even Earnings for Q4
Other News for IPSC
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101
Century Therapeutics files to sell 7.87M shares of common stock for holders
Century Therapeutics files to sell 7.87M shares of common stock for holders
Piper Sandler Sticks to Its Buy Rating for Century Therapeutics (IPSC)
Century Therapeutics price target raised by $3 at Piper Sandler, here's why